Terrazas del Rodeo

Merck asks US FDA to authorize promising anti-COVID pill

Más
1 mes 2 semanas antes #1 por Editor

Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.

“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Dr. Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit. “I think it’s a very powerful tool to add to the toolbox.”

The company reported earlier this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

apnews.com/article/coronavirus-pandemic-science-business-pandemics-medication-e731ada126414396b402c4dfc3cf8d2c

Por favor, Identificarse o Crear cuenta para unirse a la conversación.

Moderadores: Administrator
Gracias a Foro Kunena